PURPOSE: We have reported the short time effect of suplatast tosilate in the patients with pulmonary fibrosis. We have also reported that suplatast tosilate was improved lung functions by decreasing circulating Th1/Th2 lymphocyte balance in the patients with pulmonary fibrosis after 3 months.Then, we investigated the long term effect of suplatast tosilate in the patients with pulmonary fibrosis.
METHODS: Forty-six patients with chronic interstitial pneumonia ( 36 men and 10 women, mean age is 67.3 years old. 36 of IPF and 10 of non-IPF)were studied. Each patient took oral 300mg of suplatast tosilate every day from 1 to 72 months. The serum KL-6 and various lung functions were measured every 6 months.
RESULTS: Our results show that 16 of 46 patients were improved, 21 of 46 patients were stable and 9 of 46 patients were worsened in the lung functions. 4 of 46 patients were died for respiratory failure and 4 of 46 patients were showed acute exacerbation of pulmonary fibrosis. There is no different of the effect of suplatast tosilate between patients with IPF and non-IPF. Patients who stopped taking suplatast tosilate were gotten worse in the pulmonary functions compared with time when suplatast tosilate was taken.
CONCLUSION: Our results indicate that suplatast tosilate has at least stabilized effect of pulmonary functions in patients with pulmonary fibrosis.
CLINICAL IMPLICATIONS: Suplatast tosilate is a potential drug of treatment for idiopathic pulmonary fibrosis.
DISCLOSURE: Yuji Saito, No Financial Disclosure Information; No Product/Research Disclosure Information